Singapore, Sept. 30 -- Health Hope Pharma (HHP),a clinical-stage oncology biopharma company headquartered in Hong Kong, has entered into a global licensing and collaboration agreement with US-based Gilead Sciences, Inc. for encequidar, a first-in-class P-glycoprotein (P-gp) inhibitor in the field of virology.

HHP is currently exploring the potential of using encequidar to develop oral drug formulations across multiple fields. The most advanced programme of HHP is oral paclitaxel combined with encequidar in the field of oncology, targeting to replace intravenous paclitaxel in chemotherapy for metastatic breast cancer.

HHP targets to recruit the first patients for its global phase III clinical study for sites in the US and Hong Kong SAR, ...